SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Locally Advanced /Metastatic Solid Tumors
- Locally Advanced / Metastatic Solid Tumors
- Metastatic Solid Cancers
- Non Small Cell Lung Cancer
- Lung Cancer
- Melanoma
- Ovarian
- NSCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- SystImmune Inc.
- Last updated on ClinicalTrials.gov
- November 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Florida Cancer Specialists Lake Nona · Orlando, FL
- Florida Cancer Specialists Sarasota · Sarasota, FL
Tennessee · 1
- Sarah Cannon Research Institute - Oncology Partners · Nashville, TN
Texas · 1
- Mary Crowley Cancer Research · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.